NEWBURYPORT, MA — (Marketwired) — 12/09/13 — PCI Synthesis, Inc. (), a 15-year-old pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs) and other specialty chemical products, today announced a list of trends it thinks will impact the emerging biotech and generic drug industries in 2014.The FDA continues to expand its scope for oversight — most recently with a bill signed into law in November, the Drug Quality and Security Act. There-s
NEWBURYPORT, MA — (Marketwired) — 12/05/13 — PCI (), a Boston-based Contract Manufacturing Organization (CMO) that manufacturers new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and complex specialty chemicals, today announced the general availability of phosphonic acids, widely used by researchers and developers of nano-particle technology applications around the world, and the launch of its new web page .Ed Price, president of PCI, said, "More than 200 o
Named to 50 Largest Life Science Companies in Massachusetts
NEWBURYPORT, MA — (Marketwired) — 10/07/13 — PCI Synthesis, Inc. (), a custom chemical manufacturer of new chemical entities (NCE), generic active pharmaceutical ingredients (API-s), complex pharmaceutical intermediates and other specialty products, announced that industry veteran Glenn Killingworth has joined the company as the Vice President of Business Development.In his new role, Killingworth will drive business growth through the development and implementation of PCI-s sales and marketi
Brings the Company-s Total to Eight Active Pharmaceutical Ingredients (APIs) to Receive Pre-Approval/Commercial Status
Brings the CRO/CMO-s Pipeline to 13 APIs
40+ Companies Will Exhibit at February 25 Event to Highlight Local Service Providers From the Life Sciences Cluster
NEWBURYPORT, MA — (Marketwire) — 05/30/12 — PCI Synthesis, Inc. (), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced that industry veteran Alexander Tretyakov has joined the company as Vice President of Research and Development.In this role, Tretyakov will provide technical leadership across the company, specifically in creating de novo synthetic schemes and ap
March 6 Event, "Accelerating Drug Development," Focuses on Local Technology-Based Solutions
